GPhA hires ‘influential’ D.C. lobbyist
WASHINGTON — The generic drug industry’s main trade group in Washington has hired a prominent lobbyist to head its government affairs team.
The Generic Pharmaceutical Association announced that it had hired Melissa Schulman as SVP government affairs, describing her as "one of the best known advocates" in Washington, noting her ranking as an influential lobbyist in publications such as Roll Call, The Hill and National Journal. Schulman previously worked as a Democratic lobbyist for the Bockorny Group.
"[Schulman] brings a well-earned reputation for ensuring that her client’s voice is heard," GPhA president and CEO Ralph Neas said. "In addition, Melissa’s combination of 15 years of private sector experience and 14 years working in Congress makes her a perfect choice to lead our association’s advocacy efforts."
Before working for the Bockorny Group, Schulman was executive director of the Democratic Caucus and policy director Rep. Steny Hoyer, D-Md.
Diplomat VP clinical services participates in HCV ‘think tank’
FLINT, Mich. — An executive from Diplomat Specialty Pharmacy recently participated in a program on hepatitis C therapy, the company said.
Diplomat said VP clinical services Gary Rice participated in the "think tank" program, "The New Paradigm of HCV Therapy – Integration of Oral Therapies into Best Practices," at the Harvard Medical School in Boston last week. The goal of the meeting was to provide a forum for exchanging the latest knowledge and opinions on the optimal diagnosis and management of people with chronic hepatitis C, with a focus on current and experimental therapies, access to therapy, diagnosis and testing, patient care management and patient advocacy.
"Diplomat Specialty Pharmacy strives to provide the best care, resources and current information to our patients," Rice said. "To have the opportunity to participate in this Harvard think tank and meet and discuss optimal hepatitis C treatments with some of the best medical minds in the country was a privilege and an invaluable return for our patients."
FDA approves Aciphex Sprinkle capsules
WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.
Eisai announced the approval of Aciphex Sprinkle (rabeprazole sodium) delayed-release capsules.
"We are proud to offer a new treatment option for young children who suffer from GERD," Eisai president and CEO Lonnel Coats said. "Eisai is committed to keeping the medical needs of patients and their families at the forefront of all that we do as part of our human healthcare corporate mission."